DiaMedica Therapeutics Inc. (DMAC)

NASDAQ: DMAC · IEX Real-Time Price · USD

2.800

-0.150 (-5.08%)

At close: Jul 2, 2024, 4:00 PM

2.801

+0.001 (0.04%)

After-hours: Jul 2, 2024, 7:38 PM EDT

DiaMedica Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Selling, General & Admin	8.16	6.16	4.88	4.49	3.69	Upgrade
Research & Development	13.11	7.84	8.77	8.21	7.9	Upgrade
Operating Expenses	21.27	14	13.65	12.7	11.59	Upgrade
Operating Income	-21.27	-14	-13.65	-12.7	-11.59	Upgrade
Other Expense / Income	-2.01	-0.33	-0.03	-0.43	-0.98	Upgrade
Pretax Income	-19.26	-13.67	-13.61	-12.27	-10.62	Upgrade
Income Tax	0.04	0.03	0.03	0.03	0.03	Upgrade
Net Income	-19.3	-13.7	-13.64	-12.3	-10.65	Upgrade
Shares Outstanding (Basic)	33	26	21	16	12	Upgrade
Shares Outstanding (Diluted)	33	26	21	16	12	Upgrade
Shares Change	23.16%	27.29%	32.48%	30.80%	54.81%	Upgrade
EPS (Basic)	-0.60	-0.52	-0.65	-0.78	-0.89	Upgrade
EPS (Diluted)	-0.60	-0.52	-0.65	-0.78	-0.89	Upgrade
Free Cash Flow	-18.75	-11.59	-12.27	-9.22	-9.09	Upgrade
Free Cash Flow Per Share	-0.58	-0.44	-0.59	-0.59	-0.76	Upgrade
EBITDA	-19.16	-13.58	-13.53	-12.2	-10.55	Upgrade
Depreciation & Amortization	0.1	0.09	0.08	0.07	0.07	Upgrade
EBIT	-19.26	-13.67	-13.61	-12.27	-10.62	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).